1                                              MAOI treatment decreased the magnitude of both 8-OH-DPAT

2 y reduced potential for myelosuppression and MAOI.

3 ce, we report contrasting effects of chronic MAOI (phenelzine) and TCA (imipramine) treatment on neur

4 rmalize HPA function in atypical depression, MAOI would differ from TCA in decreasing rather than inc

5 oing classical monoamine oxidase inhibiting (MAOI) drug therapy.

6 uppression and monoamine oxidase inhibition (MAOI) are key independent causes for limiting adverse ef

7 mg/kg), and the monoamine oxidase inhibitor (MAOI) phenelzine (10 mg/kg) increased BDNF protein level

8 ically with the monoamine oxidase inhibitor (MAOI), clorgyline, and then injected with 8-OH-DPAT or v

9        Because monoamine oxidase inhibitors (MAOI) are often more effective than tricyclic antidepres

10 ously assessed monoamine oxidase inhibitors (MAOIs) for their ability to inhibit the reaction catalyz

11  activity with monoamine oxidase inhibitors (MAOIs) results in the accumulation of repressive chromat

12 tidepressants, monoamine oxidase inhibitors (MAOIs), fluoxetine, or placebo were examined in a retros

13 herefore, we concluded that pretreatments of MAOI pharmacologically alter the activity of postsynapti

14 ion between inhibitors of monoamine oxidase (MAOIs) and selective serotonin (5-hydroxytryptamine, 5-H

15                                  Strikingly, MAOIs also block the reactivation of HSV from latency in

16 ed in rats by once daily pretreatment of the MAOI clorgyline for 3, 6, or 13 days.

17 men had a statistically superior response to MAOIs, this difference may not be clinically relevant.

18 men had a statistically superior response to MAOIs.